334 related articles for article (PubMed ID: 32896613)
21. Nasal Drug Delivery of Anticancer Drugs for the Treatment of Glioblastoma: Preclinical and Clinical Trials.
Bruinsmann FA; Richter Vaz G; de Cristo Soares Alves A; Aguirre T; Raffin Pohlmann A; Stanisçuaski Guterres S; Sonvico F
Molecules; 2019 Nov; 24(23):. PubMed ID: 31779126
[TBL] [Abstract][Full Text] [Related]
22. Combined-therapeutic strategies synergistically potentiate glioblastoma multiforme treatment
Yang J; Shi Z; Liu R; Wu Y; Zhang X
Theranostics; 2020; 10(7):3223-3239. PubMed ID: 32194864
[TBL] [Abstract][Full Text] [Related]
23. Strategies to improve delivery of anticancer drugs across the blood-brain barrier to treat glioblastoma.
Oberoi RK; Parrish KE; Sio TT; Mittapalli RK; Elmquist WF; Sarkaria JN
Neuro Oncol; 2016 Jan; 18(1):27-36. PubMed ID: 26359209
[TBL] [Abstract][Full Text] [Related]
24. Resveratrol targeting of AKT and p53 in glioblastoma and glioblastoma stem-like cells to suppress growth and infiltration.
Clark PA; Bhattacharya S; Elmayan A; Darjatmoko SR; Thuro BA; Yan MB; van Ginkel PR; Polans AS; Kuo JS
J Neurosurg; 2017 May; 126(5):1448-1460. PubMed ID: 27419830
[TBL] [Abstract][Full Text] [Related]
25. Strategies to Improve Drug Delivery Across the Blood-Brain Barrier for Glioblastoma.
Narsinh KH; Perez E; Haddad AF; Young JS; Savastano L; Villanueva-Meyer JE; Winkler E; de Groot J
Curr Neurol Neurosci Rep; 2024 May; 24(5):123-139. PubMed ID: 38578405
[TBL] [Abstract][Full Text] [Related]
26. Nanotherapeutic treatment of the invasive glioblastoma tumor microenvironment.
Pandey N; Anastasiadis P; Carney CP; Kanvinde PP; Woodworth GF; Winkles JA; Kim AJ
Adv Drug Deliv Rev; 2022 Sep; 188():114415. PubMed ID: 35787387
[TBL] [Abstract][Full Text] [Related]
27. Bioscaffold-based study of glioblastoma cell behavior and drug delivery for tumor therapy.
Tran K; Brice R; Yao L
Neurochem Int; 2021 Jul; 147():105049. PubMed ID: 33945833
[TBL] [Abstract][Full Text] [Related]
28. CREKA peptide-conjugated dendrimer nanoparticles for glioblastoma multiforme delivery.
Zhao J; Zhang B; Shen S; Chen J; Zhang Q; Jiang X; Pang Z
J Colloid Interface Sci; 2015 Jul; 450():396-403. PubMed ID: 25863222
[TBL] [Abstract][Full Text] [Related]
29. Vesicular systems employing natural substances as promising drug candidates for MMP inhibition in glioblastoma: A nanotechnological approach.
Agarwal S; Muniyandi P; Maekawa T; Kumar DS
Int J Pharm; 2018 Nov; 551(1-2):339-361. PubMed ID: 30236647
[TBL] [Abstract][Full Text] [Related]
30. Design of Biopolymer-Based Interstitial Therapies for the Treatment of Glioblastoma.
Pena ES; Graham-Gurysh EG; Bachelder EM; Ainslie KM
Int J Mol Sci; 2021 Dec; 22(23):. PubMed ID: 34884965
[TBL] [Abstract][Full Text] [Related]
31. Engineering strategies to mimic the glioblastoma microenvironment.
Rape A; Ananthanarayanan B; Kumar S
Adv Drug Deliv Rev; 2014 Dec; 79-80():172-83. PubMed ID: 25174308
[TBL] [Abstract][Full Text] [Related]
32. Intraarterial drug delivery for glioblastoma mutiforme: Will the phoenix rise again?
Joshi S; Ellis JA; Ornstein E; Bruce JN
J Neurooncol; 2015 Sep; 124(3):333-43. PubMed ID: 26108656
[TBL] [Abstract][Full Text] [Related]
33. A comprehensive review in improving delivery of small-molecule chemotherapeutic agents overcoming the blood-brain/brain tumor barriers for glioblastoma treatment.
Wang D; Wang C; Wang L; Chen Y
Drug Deliv; 2019 Dec; 26(1):551-565. PubMed ID: 31928355
[TBL] [Abstract][Full Text] [Related]
34. Local delivery to malignant brain tumors: potential biomaterial-based therapeutic/adjuvant strategies.
Alghamdi M; Gumbleton M; Newland B
Biomater Sci; 2021 Sep; 9(18):6037-6051. PubMed ID: 34357362
[TBL] [Abstract][Full Text] [Related]
35. Nose-to-brain delivery: exploring newer domains for glioblastoma multiforme management.
Upadhaya PG; Pulakkat S; Patravale VB
Drug Deliv Transl Res; 2020 Aug; 10(4):1044-1056. PubMed ID: 32221847
[TBL] [Abstract][Full Text] [Related]
36. Pathophysiology of blood-brain barrier in brain tumor. Novel therapeutic advances using nanomedicine.
Sharma HS; Muresanu DF; Castellani RJ; Nozari A; Lafuente JV; Tian ZR; Sahib S; Bryukhovetskiy I; Bryukhovetskiy A; Buzoianu AD; Patnaik R; Wiklund L; Sharma A
Int Rev Neurobiol; 2020; 151():1-66. PubMed ID: 32448602
[TBL] [Abstract][Full Text] [Related]
37. Recent Advances on Surface-Modified GBM Targeted Nanoparticles: Targeting Strategies and Surface Characterization.
Rodà F; Caraffi R; Picciolini S; Tosi G; Vandelli MA; Ruozi B; Bedoni M; Ottonelli I; Duskey JT
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768820
[TBL] [Abstract][Full Text] [Related]
38. Prolonged survival upon ultrasound-enhanced doxorubicin delivery in two syngenic glioblastoma mouse models.
Kovacs Z; Werner B; Rassi A; Sass JO; Martin-Fiori E; Bernasconi M
J Control Release; 2014 Aug; 187():74-82. PubMed ID: 24878186
[TBL] [Abstract][Full Text] [Related]
39. Recent Advances on Glioblastoma Multiforme and Nano-drug Carriers: A Review.
Liao W; Fan S; Zheng Y; Liao S; Xiong Y; Li Y; Liu J
Curr Med Chem; 2019; 26(31):5862-5874. PubMed ID: 29768997
[TBL] [Abstract][Full Text] [Related]
40. Tumor microenvironment targeting for glioblastoma multiforme treatment via hybrid cell membrane coating supramolecular micelles.
Huang X; Mu N; Ding Y; Huang R; Wu W; Li L; Chen T
J Control Release; 2024 Feb; 366():194-203. PubMed ID: 38142965
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
